Here are four updates on GI companies from the past week.
Analysts have refuted Citron Research's report on Exact Science's Cologuard, which stated the product was a "seriously inferior product and a disastrous business model." Despite the report causing Exact Science's stock to drop 8 percent, analysts still recommend the stock.
Synthetic Biologics' C. difficile drug, ribaxamase, achieved its primary endpoint in a phase 2b trial. The drug significantly reduces C. difficile infection.
Check-Cap and GE Healthcare achieved their first development milestone when GE's developed and tested X-rays passed all tests to ensure C-scan system compliance. The companies are working to develop an ingestible capsule that will allow preparation-free colorectal cancer screening.
Takeda Pharmaceuticals' gastroenterology, oncology and emerging market platforms increased growth by 14.7 percent in fiscal year 2016.